Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aldurazyme Dose-Optimization in MPS I
NCT00144781Phase 4Completed
- Sponsor
- Sanofi
- Start
- Dec 2004
- Primary completion
- Jan 2006
- Modality
- Replacement Enzymes
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of laronidase in mucopolysaccharidosis type I (4 arms), sponsored by Sanofi. Primary endpoint: Percent Change From Baseline to Week 26 in Urinary Glycosaminoglycan (GAG) Level. Started Dec 2004; status: completed.
02
Drugs
laronidase
03
Conditions
mucopolysaccharidosis type I
Beyond the preview
Go deeper on NCT00144781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00144781.